Meeting
2022 ASCO Gastrointestinal Cancers Symposium
The impact of CA 19-9 on survival in patients with clinical stage I pancreatic cancer.
Authors
Alexa D. Melucci
Division of General Surgery, University of Rochester, Rochester, NY
Alexa D. Melucci , Alexander C Chacon , Paul R. Burchard , Nicholas A. Ullman , Vasleios Tsagkalidis , Anthony S. Casabianca , Alexandra Reitz , David A. Swift , Subir Goyal , Jeffrey M. Switchenko , Darren R. Carpizo , Mihir Maheshkumar Shah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
DOI
10.1200/JCO.2022.40.4_suppl.606
Abstract #
606
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
CA19-9 decrease and overall survival according to platelet level in patients with metastatic pancreatic cancer.
First Author: Yang Chen
Poster
2017 Gastrointestinal Cancers Symposium
CA19-9-Low & Lewis(+) pancreatic cancer: A unique subtype.
First Author: Guopei Luo
Poster
2015 ASCO Annual Meeting
Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and serum CA19-9 in unresectable pancreatic cancer (PC) patients.
First Author: Julia S. Johansen
Poster
2015 Gastrointestinal Cancers Symposium
S100P tumor-marker response to chemotherapy in patients with advanced pancreatic cancer.
First Author: Shuichi Mitsunaga